Comparative Pharmacology
Head-to-head clinical analysis: LIQUID E Z PAQUE versus RENORMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIQUID E Z PAQUE versus RENORMAX.
LIQUID E-Z-PAQUE vs RENORMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Barium sulfate is a radiopaque agent that coats the mucosal surface of the gastrointestinal tract, attenuating X-rays and providing contrast on imaging studies.
Selective beta-1 adrenergic receptor antagonist; reduces cardiac output, heart rate, and blood pressure by blocking catecholamine effects on cardiac beta-1 receptors.
Oral: 25-50 mL (barium sulfate 60% w/v) as a single dose for upper GI series; for double-contrast studies, 100-200 mL (barium sulfate 250% w/v) as a single dose. Rectal: For barium enema, 200-300 mL of a 15-20% w/v suspension instilled via enema tube.
5 mg intravenously every 12 hours
None Documented
None Documented
Not applicable (non-systemic agent); plasma half-life not clinically relevant.
Terminal elimination half-life: 8-10 hours in healthy adults. Prolonged to 18-24 hours in moderate renal impairment (CrCl 30-50 mL/min). Provides basis for twice-daily dosing in normal renal function.
Primarily fecal (oral route, unabsorbed); negligible renal excretion (<1% as intact drug).
Primarily renal (60-70% unchanged; 10-15% as glucuronide conjugate); biliary/fecal (5-10%); 80-85% total recovered in urine and feces within 72 hours.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent